Private Wealth Advisors LLC Makes New $1.09 Million Investment in Delcath Systems, Inc. (NASDAQ:DCTH)

Key Points

• Private Wealth Advisors LLC acquired 85,193 shares of Delcath Systems, Inc., valued at approximately $1,085,000, representing about 0.25% of the company's total shares.
• Delcath Systems had a successful earnings report, posting $0.07 EPS for the quarter, surpassing the consensus estimate of $0.02, with revenues of $24.16 million.
• Wall Street analysts have generally rated DCTH positively, with an average price target of $24.50 and multiple firms increasing their ratings to "buy."

Private Wealth Advisors LLC acquired a new stake in Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 85,193 shares of the company's stock, valued at approximately $1,085,000. Private Wealth Advisors LLC owned approximately 0.25% of Delcath Systems at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Jefferies Financial Group Inc. bought a new position in shares of Delcath Systems in the 4th quarter valued at about $251,000. Jane Street Group LLC boosted its stake in shares of Delcath Systems by 1,364.6% in the 4th quarter. Jane Street Group LLC now owns 178,797 shares of the company's stock valued at $2,153,000 after purchasing an additional 166,589 shares during the last quarter. Principal Financial Group Inc. boosted its stake in shares of Delcath Systems by 2.1% in the 1st quarter. Principal Financial Group Inc. now owns 117,620 shares of the company's stock valued at $1,497,000 after purchasing an additional 2,437 shares during the last quarter. Bank of America Corp DE boosted its stake in shares of Delcath Systems by 1,816.5% in the 4th quarter. Bank of America Corp DE now owns 25,700 shares of the company's stock valued at $309,000 after purchasing an additional 24,359 shares during the last quarter. Finally, Millennium Management LLC boosted its stake in shares of Delcath Systems by 53.4% in the 4th quarter. Millennium Management LLC now owns 314,675 shares of the company's stock valued at $3,789,000 after purchasing an additional 109,568 shares during the last quarter. Institutional investors and hedge funds own 61.12% of the company's stock.

Delcath Systems Stock Up 1.5%

Delcath Systems stock traded up $0.16 during midday trading on Wednesday, hitting $11.04. 395,255 shares of the stock were exchanged, compared to its average volume of 581,182. The company has a fifty day simple moving average of $12.74 and a two-hundred day simple moving average of $13.52. Delcath Systems, Inc. has a 52 week low of $7.17 and a 52 week high of $18.23. The stock has a market capitalization of $386.18 million, a PE ratio of 221.70 and a beta of 0.82.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.02 by $0.05. The firm had revenue of $24.16 million for the quarter, compared to the consensus estimate of $22.84 million. Delcath Systems had a net margin of 3.18% and a return on equity of 6.91%. As a group, equities research analysts anticipate that Delcath Systems, Inc. will post -0.79 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently issued reports on DCTH shares. HC Wainwright raised their target price on shares of Delcath Systems from $29.00 to $31.00 and gave the company a "buy" rating in a research note on Thursday, August 7th. Wall Street Zen lowered shares of Delcath Systems from a "buy" rating to a "hold" rating in a research note on Sunday. Finally, Stephens reissued an "overweight" rating and set a $25.00 price objective on shares of Delcath Systems in a research note on Monday, June 23rd. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $24.50.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.